We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is AEterna Zentaris (AEZS) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has AEterna Zentaris (AEZS - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
AEterna Zentaris is one of 840 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. AEZS is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for AEZS's full-year earnings has moved 780% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that AEZS has returned about 19.92% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -4.71% on a year-to-date basis. As we can see, AEterna Zentaris is performing better than its sector in the calendar year.
Breaking things down more, AEZS is a member of the Medical - Biomedical and Genetics industry, which includes 340 individual companies and currently sits at #76 in the Zacks Industry Rank. On average, this group has lost an average of 21.96% so far this year, meaning that AEZS is performing better in terms of year-to-date returns.
AEZS will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is AEterna Zentaris (AEZS) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has AEterna Zentaris (AEZS - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
AEterna Zentaris is one of 840 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. AEZS is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for AEZS's full-year earnings has moved 780% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that AEZS has returned about 19.92% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -4.71% on a year-to-date basis. As we can see, AEterna Zentaris is performing better than its sector in the calendar year.
Breaking things down more, AEZS is a member of the Medical - Biomedical and Genetics industry, which includes 340 individual companies and currently sits at #76 in the Zacks Industry Rank. On average, this group has lost an average of 21.96% so far this year, meaning that AEZS is performing better in terms of year-to-date returns.
AEZS will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.